Results 241 to 250 of about 1,273,562 (309)

MR GENTLE-multicentre randomised controlled trial of ghrelin in anterior circulation ischaemic stroke treated with endovascular thrombectomy: a phase 2 trial. [PDF]

Trials
Omes QPM, van der Veen D, Kersten CJBA, Arntz RM, Filius PMG, van den Wijngaard IR, van der Worp HB, Hofmeijer J.   +7 more
europepmc   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

SGL-TX-MR-study protocol acute effects of SGLT2 inhibitor on kidney allograft oxygen tension, a randomized, double-blind, placebo controlled crossover trial. [PDF]

Trials
Lange LB, Bistrup C.
europepmc   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Influence of OSCAR-IB criteria on test-retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis. [PDF]

Mult Scler
Bacchetti A, McCormack B, Lin TY, Filippatou AG, Gakis G, Pellegrini N, Kinder E, Gulati A, Lievers E, Otero-Duran G, Newsome SD, Murphy O, Nourbakhsh B, Fitzgerald KC, Sotirchos ES, Calabresi PA, Saidha S.   +16 more
europepmc   +1 more source

Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients. [PDF]

Clin Infect Dis
Limaye AP, Crespo M, Kamar N, Humar A, Carroll RP, Pereira MR, Broyde N, Wang W, Haber B.   +8 more
europepmc   +1 more source

Type 1 diabetes screening: reframing the debate from paternalism to partnership. Reply to Scaramuzza AE, Iafusco D, Cherubini V [letter] Type 1 diabetes screening: building a clinician-patient partnership for early care of chronic beta cell failure. Reply to Mallone R, Bandini A [letter]. [PDF]

Diabetologia
Gitelman SE, Simmons K, Simmons K, Sherr JL, Quattrin T, Russell WE, Sunil B, Willi SM, Knecht LA, Niemoeller E, Licaj I, Miller D, DiMeglio LA.   +12 more
europepmc   +1 more source

"Doing the Best I Can": Qualitative Outcomes and Participant Feedback From a Combined Communication and Counselling Treatment for Primary Progressive Aphasia. [PDF]

Int J Lang Commun Disord
Schaffer Mendez K, Evans WS, Dutcher CD, Philburn C, Wauters LD, Young MM, Henry ML.   +6 more
europepmc   +1 more source

Neurosurgical leadership in neuro-oncology clinical trials: A nationwide study. [PDF]

Neurosurg Rev
Ramsoomair CK, Daftari M, Desai A, Alvarez V, Himic V, Berckemeyer MA, Shlobin NA, Khalafallah AM, Wang S, Elder B, Dunn GP, Smith TR, Ivan ME, Komotar RJ, Shah AH.   +14 more
europepmc   +1 more source